Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure

Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York.

Several circulating neurohormones have been shown to have prognostic significance in patients with chronic heart failure, but the relation between plasma levels of atrial natriuretic peptide and mortality in this disorder remains unknown. Plasma levels of immunoreactive atrial natriuretic peptide were measured in 102 patients in whom left ventricular ejection fraction, ventricular arrhythmias on ambulatory electrocardiographic recording and plasma levels of norepinephrine, renin activity, aldosterone and arginine vasopressin were also measured. Compared with patients with atrial natriuretic peptide concentrations below the median value of 125 pg/ml, patients with higher levels of the peptide had a higher plasma renin activity (8.9 +/- 1.8 versus 2.6 +/- 0.4 ng/ml per h) and plasma norepinephrine (858 +/- 116 versus 538 +/- 45 pg/ml), more frequent premature ventricular depolarizations (4,485 +/- 715 versus 2,004 +/- 495/day) and more advanced hemodynamic abnormalities (all p less than 0.05). During the subsequent 13 to 25 months of follow-up, patients with high levels of atrial natriuretic peptide had a significantly lower rate of survival than did those whose initial circulating peptide concentrations were normal or mildly increased (p = 0.01). These data indicate that, in patients with chronic heart failure, plasma atrial natriuretic peptide provides important prognostic information. This may relate to the ability of the hormone to reflect the interplay of several pathophysiologic factors that contribute to mortality in this disease.

This article has been cited by other articles:

				M. Huelsmann, S. Neuhold, G. Strunk, D. Moertl, R. Berger, R. Prager, H. Abrahamian, M. Riedl, R. Pacher, A. Luger, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus Eur. Heart J., September 2, 2008; 29(18): 2259 - 2264. [Abstract] [Full Text] [PDF]

				H. B. Suliman, K. E. Welty-Wolf, M. Carraway, L. Tatro, and C. A. Piantadosi Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis Cardiovasc Res, November 1, 2004; 64(2): 279 - 288. [Abstract] [Full Text] [PDF]

				K. L. Tran, X. Lu, M. Lei, Q. Feng, and Q. Wu Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1625 - H1631. [Abstract] [Full Text] [PDF]

				L. Menezes Falcao, F. Pinto, L. Ravara, and P. A. van Zwieten BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 121 - 129. [Abstract] [PDF]

				R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF]

				M. P. van den Berg, I. C. van Gelder, and D. J. van Veldhuisen Depletion of atrial natriuretic peptide during longstanding atrial fibrillation Europace, January 1, 2004; 6(5): 433 - 437. [Abstract] [Full Text] [PDF]

				H. Ohuchi, H. Takasugi, H. Ohashi, Y. Okada, O. Yamada, Y. Ono, T. Yagihara, and S. Echigo Stratification of Pediatric Heart Failure on the Basis of Neurohormonal and Cardiac Autonomic Nervous Activities in Patients With Congenital Heart Disease Circulation, November 11, 2003; 108(19): 2368 - 2376. [Abstract] [Full Text] [PDF]

				U. Elkayam, M. W. Akhter, P. Tummala, S. Khan, and H. Singh Nesiritide: A New Drug for the Treatment of Decompensated Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 181 - 194. [Abstract] [PDF]

				A. P. Bolger, R. Sharma, W. Li, M. Leenarts, P. R. Kalra, M. Kemp, A. J.S. Coats, S. D. Anker, and M. A. Gatzoulis Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease Circulation, July 2, 2002; 106(1): 92 - 99. [Abstract] [Full Text] [PDF]

				M. Hulsmann, R. Berger, B. Sturm, A. Bojic, W. Woloszczuk, J. Bergler-Klein, and R. Pacher Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure Eur. Heart J., June 1, 2002; 23(11): 886 - 891. [Abstract] [Full Text] [PDF]

				F. Wu, W. Yan, J. Pan, J. Morser, and Q. Wu Processing of Pro-atrial Natriuretic Peptide by Corin in Cardiac Myocytes J. Biol. Chem., May 3, 2002; 277(19): 16900 - 16905. [Abstract] [Full Text] [PDF]

				I. S. Anand, V. G. Florea, and L. Fisher Surrogate end points in heart failure J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1414 - 1421. [Abstract] [Full Text] [PDF]

				M. Imazio, M. Bobbio, F. Broglio, A. Benso, V. Podio, M.R. Valetto, G. Bisi, E. Ghigo, and G.P. Trevi GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy Eur J Heart Fail, March 1, 2002; 4(2): 185 - 191. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Fujii, T. Matsumoto, T. Yamamoto, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1485 - 1490. [Abstract] [Full Text] [PDF]

				A. T. Yan, T. D. Bradley, and P. P. Liu The Role of Continuous Positive Airway Pressure in the Treatment of Congestive Heart Failure Chest, November 1, 2001; 120(5): 1675 - 1685. [Abstract] [Full Text] [PDF]

				C. Zugck, C. Kruger, R. Kell, S. Korber, D. Schellberg, W. Kubler, and M. Haass Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model Eur J Heart Fail, October 1, 2001; 3(5): 577 - 585. [Abstract] [Full Text] [PDF]

				F. Boomsma and A. H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res, August 15, 2001; 51(3): 442 - 449. [Full Text] [PDF]

				P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]

				M. G. Andreassi, S. Del Ry, C. Palmieri, A. Clerico, A. Biagini, and D. Giannessi Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones Eur J Heart Fail, August 1, 2001; 3(4): 407 - 414. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1228 - 1233. [Abstract] [Full Text] [PDF]

				G. A Sagnella Practical implications of current natriuretic peptide research Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315. [PDF]

				K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1587 - 1593. [Abstract] [Full Text] [PDF]

				M. R COWIE BNP: soon to become a routine measure in the care of patients with heart failure? Heart, June 1, 2000; 83(6): 617 - 618. [Full Text]

				T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 714 - 721. [Abstract] [Full Text] [PDF]

				T. Yamada, M. Fukunami, T. Shimonagata, K. Kumagai, H. Ogita, Y. Asano, A. Hirata, M. Hori, and N. Hoki Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study J. Am. Coll. Cardiol., February 1, 2000; 35(2): 405 - 413. [Abstract] [Full Text] [PDF]

				T. E. Lohmeier, H. L. Mizelle, G. A. Reinhart, and J.-P. Montani Influence of angiotensin on the early progression of heart failure Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2000; 278(1): R74 - R86. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, M. Hayashi, M. Ohnishi, M. Sawaki, M. Fujii, H. Horie, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1 Eur. Heart J., December 2, 1999; 20(24): 1799 - 1807. [Abstract] [PDF]

				R. W. Braith, M. A. Welsch, M. S. Feigenbaum, H. A. Kluess, and C. J. Pepine Neuroendocrine activation in heart failure is modified by endurance exercise training J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1170 - 1175. [Abstract] [Full Text] [PDF]

				S. D. Anker and M. Rauchhaus Heart failure as a metabolic problem Eur J Heart Fail, June 1, 1999; 1(2): 127 - 131. [Abstract] [Full Text] [PDF]

				M. Hulsmann, B. Stanek, B. Frey, B. Sturm, D. Putz, T. Kos, R. Berger, W. Woloszczuk, G. Maurer, and R. Pacher Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1695 - 1700. [Abstract] [Full Text] [PDF]

				E. R. Levin, D. G. Gardner, and W. K. Samson Natriuretic Peptides N. Engl. J. Med., July 30, 1998; 339(5): 321 - 328. [Full Text] [PDF]

				D. R Murdoch, J. Byrne, J. J Morton, T. A McDonagh, S. D Robb, S. Clements, I. Ford, J. J V McMurray, and H. J Dargie Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice Heart, December 1, 1997; 78(6): 594 - 597. [Abstract] [Full Text] [PDF]

				S. Neubauer, M. Horn, M. Cramer, K. Harre, J. B. Newell, W. Peters, T. Pabst, G. Ertl, D. Hahn, J. S. Ingwall, et al. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy Circulation, October 7, 1997; 96(7): 2190 - 2196. [Abstract] [Full Text]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]

				T. De Marco and L. Goldman Predicting Outcomes in Severe Heart Failure Circulation, June 17, 1997; 95(12): 2597 - 2599. [Full Text]

				K. D. Aaronson, J. S. Schwartz, T.-M. Chen, K.-L. Wong, J. E. Goin, and D. M. Mancini Development and Prospective Validation of a Clinical Index to Predict Survival in Ambulatory Patients Referred for Cardiac Transplant Evaluation Circulation, June 17, 1997; 95(12): 2660 - 2667. [Abstract] [Full Text]

				C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]

				T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text]

				K. B. James, P. M. McCarthy, S. Jaalouk, E. L. Bravo, A. Betkowski, J. D. Thomas, S. Nakatani, and F. M. Fouad-Tarazi Plasma Volume and Its Regulatory Factors in Congestive Heart Failure After Implantation of Long-term Left Ventricular Assist Devices Circulation, April 15, 1996; 93(8): 1515 - 1519. [Abstract] [Full Text]

				K. B. James, P. M. McCarthy, J. D. Thomas, R. Vargo, R. E. Hobbs, S. Sapp, and E. Bravo Effect of the Implantable Left Ventricular Assist Device on Neuroendocrine Activation in Heart Failure Circulation, November 1, 1995; 92(9): 191 - 195. [Abstract] [Full Text]

				G. Iervasi, A. Clerico, S. Berti, A. Pilo, A. Biagini, R. Bianchi, and L. Donato Altered Tissue Degradation and Distribution of Atrial Natriuretic Peptide in Patients With Idiopathic Dilated Cardiomyopathy and Its Relationship With Clinical Severity of the Disease and Sodium Handling Circulation, April 1, 1995; 91(7): 2018 - 2027. [Abstract] [Full Text]

				P. R. Marantz, J. N. Tobin, S. Wassertheil-Smoller, C. Ahn, R. M. Steingart, and J. P. Wexler Prognosis in Ischemic Heart Disease: Can You Tell as Much at the Bedside as in the Nuclear Laboratory? Arch Intern Med, December 1, 1992; 152(12): 2433 - 2437. [Abstract] [PDF]

				K. M. Davis, L. C. Fish, D. Elahi, B. A. Clark, and K. L. Minaker Atrial Natriuretic Peptide Levels in the Prediction of Congestive Heart Failure Risk in Frail Elderly JAMA, May 20, 1992; 267(19): 2625 - 2629. [Abstract] [PDF]